Gaudium IVF and Women Health Limited (GAUDIUMIVF) — Announcement | 19 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Gaudium IVF reports 9.1% YoY revenue growth to ₹19.4 crores in Q1 FY27 amid expansion investments.
🔄 What Changed
EBITDA margin declined to 12.5% from 29% due to expansion costs; underlying EBITDA estimated at ₹5.35 crores (27.6% margin) excluding one-time costs.
🔮 What's Next
Target 30% FY27 revenue growth and stable EBITDA margins; 10 new hubs planned for FY27; Lucknow Women's Hospital funded via internal accruals.
💡 Investor Takeaway
Shareholders should note that near-term margin pressure reflects strategic investments in scalable infrastructure and AI differentiation, positioning the company for long-term growth in a high-potential market.

Gaudium IVF reported 9.1% YoY revenue growth to ₹19.4 crores in Q1 FY27, driven by patient volume and international demand, though EBITDA margin moderated to 12.5% due to expansion investments. The company launched its first AI-powered Signature Lab in South Extension, plans to open 10 new hubs in FY27, and highlighted AI tools SiD and ERICA boosting success rates by 8%. With a strong balance sheet (₹8.12 crores cash, debt-to-equity of 0.04x) and ₹25 crores capex for FY27 hubs, management targets 30% revenue growth while maintaining FY26-adjusted EBITDA margins. International patient share stands at 25-30%, underscoring growing global demand for standardized, AI-enhanced fertility care.

📄 View Original Announcement (PDF)

About Gaudium IVF and Women Health Limited (GAUDIUMIVF)

Healthcare · Healthcare · Listed on NSE

Market Cap: ₹861.07 Cr P/E: 31.9 ROE: 50.0% ROCE: 52.1%

View full GAUDIUMIVF stock details →

📡 Get AI alerts when GAUDIUMIVF files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GAUDIUMIVF — Free

📊 More GAUDIUMIVF filings

See all GAUDIUMIVF filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GAUDIUMIVF files new disclosures

Track GAUDIUMIVF filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GAUDIUMIVF — Free

Free account · 2 AI queries/day